ロード中...
Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283
Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug si...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4179499/ https://ncbi.nlm.nih.gov/pubmed/25107642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.07.038 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|